Medications highlighted in the graphic include: Oral Wegovy - GLP-1 receptor agonist - ~13 to 17% estimated weight loss Wegovy 7.2 mg - Higher-dose injectable GLP-1 - ~20 to 21% estimated weight loss Orforglipron - Oral non-peptide GLP-1 agonist - ~11 to 15% estimated weight loss CagriSema - Amylin analog + GLP-1 agonist - ~20 to 23% estimated weight loss Retatrutide - Triple agonist (GIP, GLP-1, glucagon) - up to ~28 to 29% estimated weight loss Survodutide - Dual agonist (GLP-1, glucagon) - ~15 to 19% estimated weight loss MariTide - GIP antagonist + GLP-1 antibody-drug conjugate - ~18 to 20% estimated weight loss A few important notes for context: The percentages shown are trial-based estimates and vary by dose, duration, and analysis method Timelines reflect best estimates, not guarantees Real-world outcomes will depend on access, tolerability, and individualized care That said, the direction is clear
Side effects, such as mild nausea, typically subside as your body adjusts
Once reconstituted, they should be kept refrigerated at 2C to 8C and used within the recommended timeframe
[DOI] [PubMed] [Google Scholar] 42.Yagishita Y., Uruno A., Chartoumpekis D.V., Kensler T.W., Yamamoto M
It is marketed as a drug to alleviate neuropathic pain, and there are suggestions that it may help with cognitive and mood disorders
